Association between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study-Reference-Cited by-同舟云学术

Association between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study

Published:2015-05-12 Issue:5 Volume:10 Page:e0126579
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Konno Shingo,Suzuki Shigeaki,Masuda Masayuki,Nagane Yuriko,Tsuda Emiko,Murai Hiroyuki,Imai Tomihiro,Fujioka Toshiki,Suzuki Norihiro,Utsugisawa Kimiaki

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference10 articles.

1. Clinical practice. Glucocorticoid-induced bone disease;RS Weinstein;N Engl J Med,2011

2. Effects of low-dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis: a meta-analysis;YH Lee;J Investig Med,2008

3. Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus;J Jacobs;Osteoporos Int,2013

4. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity;MN Meriggioli;Lancet Neurol,2009

5. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America;A Jaretzki 3rd;Neurology,2000

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Bone Density Changes and Fracture Risk in Myasthenia Gravis: Implications for FRAX® Tool Application;Healthcare;2024-09-08

2. The association between myasthenia gravis and risk of fracture: a systematic review and meta-analysis;Osteoporosis International;2024-05-15

3. Ten-year fracture risk in Japanese patients with myasthenia gravis: A comprehensive assessment using the fracture risk assessment tool;Journal of the Neurological Sciences;2024-05

4. Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis;European Journal of Neurology;2024-03-24

5. Impact of early introduction of biologics on internal medications for neuromyelitis optica spectrum disorder;Clinical and Experimental Neuroimmunology;2023-07-13